Oral semaglutide formulation III investigates PK with different tablet versions, water volumes, and meal delays in healthy men
Background
Type 2 Diabetes and obesity are chronic conditions requiring effective, convenient treatments. Semaglutide, a potent GLP-1R agonist, is highly effective but typically administered via injection. Oral peptide delivery faces significant challenges due to enzymatic degradation and poor absorption in the gastrointestinal tract. Developing optimized oral formulations is crucial to improve patient adherence and expand access to this class of therapeutics, addressing the need for non-injectable options.
Study Design
This Phase 1, randomized, crossover study enrolled 384 healthy male participants. Each participant received oral semaglutide from two different tablet versions (Formulation III) for 10 days in two separate treatment periods. The study investigated pharmacokinetic properties, specifically the amount of semaglutide in the blood, after daily oral administration. Key variables explored included the impact of different water volumes and tablet-meal delays on drug absorption and exposure. The total study duration per participant was approximately 23 weeks.
Why It Matters
Optimizing oral peptide delivery is critical for patient adherence and broader therapeutic access. This study's investigation into semaglutide Formulation III, particularly its focus on water volume and meal timing, directly addresses practical aspects of oral administration. Successful development of an improved oral semaglutide formulation could significantly enhance convenience for patients with type 2 diabetes and obesity, potentially reducing reliance on injectable forms. The findings could inform future dosing protocols, making oral semaglutide more robust and less sensitive to specific consumption conditions, thereby improving real-world effectiveness and user experience.
semaglutide
oral formulation
pharmacokinetics
phase 1
healthy men
type 2 diabetes